Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00716820 |
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Condition | Intervention | Phase |
---|---|---|
Gastrointestinal Stromal Tumors |
Drug: SUNITINIB MALATE |
Phase IV |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Special Investigation For Gist Of Sutent (Regulatory Post Marketing Commitment Plan). |
Estimated Enrollment: | 600 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | June 2013 |
Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
SUNITINIB MALATE
Patients taking Sutent.
|
Drug: SUNITINIB MALATE
SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated. The dosage may be decreased according to the patient's clinical condition."
|
All the patients whom an investigator prescribes the first SUNITINIB MALATE(Sutent) should be registered.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
The patients whom an investigator involving A6181175 prescribes the SUNITINIB MALATE(Sutent).
Inclusion Criteria:
Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the surveillance.
Exclusion Criteria:
Patients not administered SUNITINIB MALATE(Sutent).
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A6181175 |
Study First Received: | July 15, 2008 |
Last Updated: | July 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00716820 History of Changes |
Health Authority: | Japan: Institutional Review Board |
Digestive System Diseases Digestive System Neoplasms Sunitinib Gastrointestinal Diseases |
Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Angiogenesis Inhibitors |
Digestive System Neoplasms Gastrointestinal Diseases Antineoplastic Agents Growth Substances Physiological Effects of Drugs Angiogenesis Inhibitors Pharmacologic Actions Neoplasms |
Neoplasms by Site Digestive System Diseases Sunitinib Therapeutic Uses Gastrointestinal Neoplasms Growth Inhibitors Angiogenesis Modulating Agents Gastrointestinal Stromal Tumors |